Johnson & Johnson at Raymond James Institutional Investors Conference (Virtual) Transcript
Okay. I think we're going to get started now. So good morning, and welcome to the 42nd Annual Raymond James Institutional Investors Conference. My name is Jayson Bedford. I cover the medical device sector at Raymond James.
So it's really our pleasure to have J&J with us this morning, a name that's obviously been in the news quite a bit over the last few days for the great work they've done on the vaccine and the important role they'll play in getting us all back to a state of, let's call it, improved normalization.
So with us from J&J, we have the company's CFO, Joe Wolk; the company's VP of Investor Relations, Chris DelOrefice; and Senior Director of Investor Relations, Lisa Romanko.
Questions & Answers
So with that, Joe, first, obviously, congratulations on the vaccine. The
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |